Plain-English translation of NCT05182957 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing a combination of three medications: an , , and . These three drugs work in different ways to fight cancer cells, and researchers believe they may work better together than separately. The study is looking at whether this combination can help people with peripheral T-cell lymphoma that has come back or stopped responding to earlier treatments.
Peripheral T-cell lymphoma is a rare blood cancer that is difficult to treat, and most patients don't survive more than 5 years after diagnosis. Standard first-line chemotherapy doesn't work well for many patients, so researchers are studying whether combining newer medications with different mechanisms of action might improve outcomes for people whose cancer has returned or is no longer responding to treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would receive the three-drug combination treatment as an outpatient. You would likely have regular clinic visits for blood tests, scans, and check-ups to see how well the medication is working and to monitor for side effects. The exact schedule would be explained to you during enrollment, but you can expect ongoing visits over several months to assess your response to treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China